Aperture Bio to Begin Accepting Pre-orders for its RAPIB-B(TM) Quantitative Microbiology Platform for Rapid Detection of Bacterial Infections with Antibiotic Guidance

(Dallas, TX – 6/24/19) - www.Aperturebio.com. In response to the growing demand for advanced diagnostic tools to aid in the fight of overused and misused antibiotics, Aperture Bio has begun accepting pre-orders of its RAPID-B(TM) and its empiriSTAT menu of diagnostic tests.

In a statement from Aperture Bio’s president, David Potenza, “With world health agencies calling for increased action to combat resistance, and no new antibiotics on the horizon, healthcare providers, laboratory directors and infection control officers are looking for technology to ease the burden of overused antibiotics.”

The World Health Organization (WHO) states, “Antibiotic resistance is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally. Without urgent action, we are heading for a post- antibiotic era in which common infections and minor injuries can once again kill."

Utilizing highly customized and fully robotic, flow cytometric technology (nFC) and fluidics, coupled with proprietary selection algorithms and customized platting, the RAPID-B(TM) platform can discriminate, along with other contaminants, live uropathogen cells from those that are dead/damaged, which could result in false positives. Utilizing a sensitive array of lasers, the system then enumerates only viable bacteria and white blood cells within minutes and provides Antibiotic Predictive Profiling (APP) within hours. Specifically knowing which patients to treat and what to best to treat them with could greatly reduce the risks for millions of patients being unnecessarily overexposed to antibiotics and saving millions in healthcare costs.

The speed and accuracy of the empiriSTAT test has demonstrated to out-perform other screening methods including chemical strips, microscopy and PCR. Even standard urinalysis screening, which is semiquantitative and lacks precision and standardization, results in a high rate of mis-interpretation, which can lead to under-treatment, or more often, over-treatment with empirical antibiotics. When compared to current screening and culture methodology, accompanied with follow through AST testing, which all can take days, the RAPID-B(TM) could change how bacterial infections are detected and treated, disrupting the multi-billion-dollar laboratory testing industry.

Achieving 97% sensitivity and 87% specificity, the empiriSTAT-UTI, is the first in a series of in vitro tests developed to increase the speed and accuracy of identifying bacterial infections from both urine and blood. The speed and accuracy of the test will reduce days into hours when compared to current screen, culture and reflexed Antibiotic Susceptibility Testing (AST.) By rapidly isolating those patients that are negative vs. positive, aids healthcare professionals to quickly and accurately identify not only those patients that may require treatment, but as important, those that do not require antibiotic treatments.

With reports suggesting that +/-80% of blood and +/-60% of urine cultures come back negative, the ability to accurately and rapid discriminate positive vs. negative patients within minutes, could significantly reduce the over-use and mis-use of antibiotics, which is at the the foundation of the antibiotic resistance pandemic. The unintentional over-use or mis-uses, is in great part due to the empirical over-prescribing of antibiotics in a somewhat blind, defensive response by caregivers as the wait for results.

David Potenza
President
dpotenza@aperturebio.com
20 Winter Sports Ln
Williston, VT 05495

About Aperture Bio – Aperture Bio is a privately held laboratory diagnostic company whose focus is to bring emerging technologies to market aimed at addressing antibiotic resistance and other world health issues. The company is currently seeking B Series investors to further expand its product offering and the commercialization of its proprietary RAPID-B(TM) platform. For investment opportunities, please contact Mr. David Potenza dpotenza@aperturebio.com

This release was published on openPR.